A KHN data analysis finds the door of opportunities connecting Capitol Hill, the federal government, and the drug industry likely spins in Big Pharma’s favour. Exhibit A: Alex Azar.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
Congenica has announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. He has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses.
Former drug industry executive, Alex Azar was confirmed by a Senate vote on Wednesday as the next secretary of the Department of Health and Human Services.
To help you plan your visit, or perhaps inspire you to sign up for your free place, we’ve put together a handy guide to this year’s theme, and some of our top picks from the agenda.
The National Institutes of Health have announced that it will launch an effort to remove barriers from the adoption of genome editing for treating patients.
Consumption of dietary fibre can prevent obesity, metabolic syndrome and adverse changes in the intestine by promoting growth of “good” bacteria in the colon.
Southern Illinois University’s medical school has halted all herpes research, one of its most high-profile projects, amid growing controversy over a researcher’s unauthorized methods offshore and in the U.S.
Sick and tired of dealing with generic drug shortages and unpredictable price increases, five large U.S. health systems are taking an unusual step: they’re forming their own nonprofit generic drugmaker.
The FDA has approved the very first algorithm that monitors a patient’s vitals to help predict sudden death from heart attacks or respiratory failure.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
Although very much disagreeing with biohacking practices, and strongly discouraging them, the FDA has never actually intervened themselves with individuals. Should they?
“The Disconnect Between the ‘Promise’ and the ‘Actual Impact’ is the Biggest Challenge in -Omics Based Technologies” – Zisis Kozlakidis
We’ve sat down with Dr Zisis Kozlakidis before his talk ‘Tracking Viruses in Space and Time’ at the Festival of Genomics in London 2018, were we talk virus.
After raising $20 million in funding, Stratos Genomics is hoping that its DNA sequencing technology will take the field further as it prepares to break into the market in the coming year.